Prevalence of RPGR-Mediated Retinal Dystrophy in an Unselected Cohort of Over 5000 Patients.
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
03 01 2022
03 01 2022
Historique:
entrez:
5
1
2022
pubmed:
6
1
2022
medline:
27
1
2022
Statut:
ppublish
Résumé
Comprehensive genetic testing for inherited retinal dystrophy (IRD) is challenged by difficult-to-sequence genomic regions, which are often mutational hotspots, such as RPGR ORF15. The purpose of this study was to evaluate the diagnostic contribution of RPGR variants in an unselected IRD patient cohort referred for testing in a clinical diagnostic laboratory. A total of 5201 consecutive patients were analyzed with a clinically validated next-generation sequencing (NGS)-based assay, including the difficult-to-sequence RPGR ORF15 region. Copy number variant (CNV) detection from NGS data was included. Variant interpretation was performed per the American College of Medical Genetics and Genomics guidelines. A confirmed molecular diagnosis in RPGR was found in 4.5% of patients, 24.0% of whom were females. Variants in ORF15 accounted for 74% of the diagnoses; 29% of the diagnostic variants were in the most difficult-to-sequence central region of ORF15 (c.2470-3230). Truncating variants made up the majority (91%) of the diagnostic variants. CNVs explained 2% of the diagnostic cases, of which 80% were one- or two-exon deletions outside of ORF15. Our findings indicate that high-throughput, clinically validated NGS-based testing covering the difficult-to-sequence region of ORF15, in combination with high-resolution CNV detection, can help to maximize the diagnostic yield for patients with IRD. These results demonstrate an accurate and scalable method for the detection of RPGR-related variants, including the difficult-to-sequence ORF15 hotspot, which is relevant given current and emerging therapeutic opportunities.
Identifiants
pubmed: 34985506
pii: 2778227
doi: 10.1167/tvst.11.1.6
pmc: PMC8742508
doi:
Substances chimiques
Eye Proteins
0
RPGR protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6Références
Am J Hum Genet. 2003 Nov;73(5):1131-46
pubmed: 14564670
Genet Med. 2020 Jun;22(6):1079-1087
pubmed: 32037395
Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1411-6
pubmed: 23372056
Hum Mutat. 2002 May;19(5):486-500
pubmed: 11968081
Mol Vis. 2008 Jun 06;14:1081-93
pubmed: 18552978
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Arch Ophthalmol. 2007 Feb;125(2):151-8
pubmed: 17296890
Expert Opin Orphan Drugs. 2018 Feb 27;6(3):167-177
pubmed: 30057863
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4123-4133
pubmed: 30105367
Nat Protoc. 2016 Jan;11(1):1-9
pubmed: 26633127
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8232-7
pubmed: 23150612
Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4434-4440
pubmed: 30193314
J Med Genet. 2016 Sep;53(9):600-7
pubmed: 27208209
J Mol Diagn. 2016 Nov;18(6):817-824
pubmed: 27620828
Ophthalmology. 2017 Sep;124(9):1314-1331
pubmed: 28559085
Prog Retin Eye Res. 2021 May;82:100898
pubmed: 32860923
Genes (Basel). 2019 Sep 04;10(9):
pubmed: 31487940
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Invest Ophthalmol Vis Sci. 2014 Aug 05;55(10):6213-23
pubmed: 25097241
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Am J Hum Genet. 2017 Jan 5;100(1):75-90
pubmed: 28041643